Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on oral pharmacologic treatment of type 2 diabetes in adults. This guideline serves as an update to the 2012 ACP guideline on the same topic. This guideline is endorsed by the American Academy of Family Physicians.
D
iabetes mellitus is the seventh leading cause of death in the United States. It also is a leading cause of morbidity, resulting in both microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (coronary artery, cerebrovascular, and peripheral vascular disease) complications. Type 2 diabetes mellitus is the most common form of the disease (affecting 90% to 95% of persons with diabetes), with a prevalence of approximately 29.1 million people in the United States (1). The risk for type 2 diabetes increases with age, and nearly 26% of people in the United States older than 65 years have diabetes (1). In addition, because of the rising obesity rate in the United States, the incidence and prevalence of diabetes mellitus are increasing substantially (2). The total direct and indirect costs associated with diabetes in the United States alone reached $245 billion in 2012 (1).
Management of type 2 diabetes often includes lifestyle modification and pharmacologic therapy. In the United States, several unique classes of drugs are approved by the U.S. Food and Drug Administration (FDA) to treat hyperglycemia in type 2 diabetes, all of which vary regarding cost and harms. Most adults diagnosed with type 2 diabetes receive treatment with oral medications only rather than injection medications, such as insulin or glucagon-like peptide-1 (GLP-1) receptor agonists (3).
GUIDELINE FOCUS AND TARGET POPULATION
Since the publication of the 2012 American College of Physicians (ACP) guideline on the comparative effectiveness and safety of oral medications for the treatment of type 2 diabetes, several new studies evaluated medications for this disease, and the FDA approved several new agents. New information in the up-dated review includes evidence on the FDA-approved sodium-glucose cotransporter-2 (SGLT-2) inhibitor class of drugs and on additional dipeptidyl peptidase-4 (DPP-4) inhibitors, as well as further evidence on other drugs included in the 2011 review. The purpose of this ACP guideline is to present the updated evidence regarding the oral pharmacologic treatment of type 2 diabetes; it replaces the 2012 ACP guideline on the same topic (4). The target audience for this guideline includes all clinicians, and the target patient population includes all adults with type 2 diabetes. These recommendations are based on a systematic evidence review sponsored by the Agency for Healthcare Research and Quality (AHRQ) (5) as well as a recently published update of the review (6). Although the focus of this guideline is oral pharmacologic therapy, lifestyle modifications are an important management strategy for type 2 diabetes. Injectable medications, including insulin, also are important treatments, although most patients prefer oral agents as initial therapy. This guideline is endorsed by the American Academy of Family Physicians.
METHODS

Systematic Review of the Evidence
The evidence review was conducted by the AHRQ Johns Hopkins Evidence-based Practice Center. Additional methodological details can be found in the Appendix (available at www.annals.org), the full report (5), and the published article (6). Reviewers searched several databases for studies published in English from April 2009 through March 2015. An updated search through December 2015 found evidence that changed from low or insufficient quality to high or moderate quality. Reviewers combined data when possible by using meta-analysis and assessed risk of bias and study quality according to established methodology. The study population included adults (aged ≥18 years) with type 2 diabetes.
The review evaluated head-to-head comparisons of oral monotherapy with metformin, thiazolidinediones, sulfonylureas, DPP-4 inhibitors, and SGLT-2 inhibitors; comparisons of metformin monotherapy with a metformin-based combination; and comparisons of metformin-based combinations in which the second medication was one of the monotherapies described earlier. The review contains additional information on injectables, including GLP-1 receptor agonists and insulin, which is not considered in the guideline. Evaluated outcomes included intermediate outcomes of hemoglobin A 1c (HbA 1c ) levels, weight, systolic blood pressure (for SGLT-2 inhibitors only), and heart rate (for SGLT-2 inhibitors only); all-cause mortality; cardiovascular and cerebrovascular morbidity and mortality; retinopathy, nephropathy, and neuropathy; and harms.
Grading the Evidence and Developing Recommendations
This guideline was developed by the ACP Clinical Guidelines Committee (CGC) according to ACP's guideline development process, details of which can be found in the methods paper (7). This guideline rates the evidence and recommendations by using ACP's guideline grading system ( Table 1) .
Peer Review
The AHRQ evidence review was sent to invited peer reviewers and posted on the AHRQ Web site for public comments, and the published review article was peer reviewed through the journal. The guideline was peer reviewed through the journal and posted online for comments from ACP Regents and Governors, who represent physician members at the regional level.
COMPARATIVE BENEFITS OF ORAL MEDICATIONS FOR TYPE 2 DIABETES
Long-Term All-Cause Mortality, Microvascular, and Macrovascular Outcomes
Evidence from new studies (52 randomized, controlled trials and 13 observational studies, mostly 1 year or less in duration) was either low quality or insufficient for evaluating clinical outcomes, such as mortality, cardiovascular mortality and morbidity, retinopathy, nephropathy, and neuropathy.
All-Cause Mortality
Low-quality evidence comparing metformin monotherapy with sulfonylurea monotherapy showed that metformin was associated with lower all-cause mortality; however, results were inconsistent across studies (8 -16) . Generally, if low-quality evidence was available for all-cause mortality, it showed no difference between monotherapies and combination therapies.
Cardiovascular Mortality
The review found moderate-quality evidence that metformin was associated with lower cardiovascular mortality (≥2 years) than sulfonylureas, on the basis of 2 randomized, controlled trials (8, 9) and 3 nonexperimental studies (10, 11, 17) . The CGC reviewed the individual studies and found the 2 trials to be underpowered, with no significant reductions in cardiovascular mortality with metformin versus sulfonylureas, and therefore considered the quality of evidence to be low. The committee also noted that in 2 of the nonexperimental studies, the combination of metformin and a sulfonylurea significantly reduced overall (9) and cardiovascular (16) mortality compared with a sulfonylurea alone.
Evidence for all other comparisons was insufficient or low quality.
Cardiovascular and Cerebrovascular Morbidity
Low-quality evidence showed that metformin monotherapy was associated with lower cardiovascular morbidity than sulfonylurea monotherapy, although results were inconsistent across studies (8 -16) . Evidence for all other comparisons was insufficient or low quality, thus inconclusive for this outcome.
Retinopathy, Nephropathy, and Neuropathy
All randomized, controlled trials were short term, and evidence for all comparisons was insufficient or low quality, thus inconclusive for these outcomes.
Intermediate Outcomes
HbA 1c Levels
Monotherapy Versus Monotherapy. As in the 2012 guideline, most diabetes medications had similar efficacy in reducing HbA 1c levels. High-quality evidence from the 2011 review showed no difference between metformin and sulfonylureas regarding their effect on HbA 1c levels (hence, evidence was not updated) (18). High-quality evidence also showed no difference between metformin and thiazolidinediones (19 -41) or between thiazolidinediones and sulfonylureas in reducing HbA 1c levels (32, 35, 40 -52) . High-quality evidence showed that metformin reduced HbA 1c levels to a greater extent than DPP-4 inhibitors (mean betweengroup difference, Ϫ0.43% [CI, Ϫ0.55% to Ϫ0.31%]) (37, 53-60), and moderate-quality evidence favored sulfonylureas over DPP-4 inhibitors (mean between-group difference, Ϫ0.21% [CI, Ϫ0.32% to Ϫ0.09%]) (61-63). Low-quality evidence showed no difference between metformin and SGLT-2 inhibitors (64 -66 (63, 76 -79) . Moderate-quality evidence showed no difference between metformin plus a thiazolidinedione and metformin plus a sulfonylurea (80 -87) . Moderate-quality evidence also showed no substantial differences regarding most other comparisons.
Weight
Monotherapy Versus Monotherapy. According to high-quality evidence from the 2011 review, metformin reduced weight more than thiazolidinediones (pooled mean between-group difference, Ϫ2.6 kg [CI, Ϫ4.1 to Ϫ1.2 kg]) or sulfonylureas (pooled mean betweengroup difference, Ϫ2.7 kg [CI, Ϫ3.5 to Ϫ1.9 kg]) (hence, evidence was not updated) (18). High-quality evidence also showed that metformin was more favorable than DPP-4 inhibitors for weight reduction (pooled mean between-group difference, Ϫ1.3 kg [CI, Ϫ1.6 to Ϫ1.0 kg]) (37, (53) (54) (55) (56) (57) (58) (59) (60) . Moderate-quality evidence showed that SGLT-2 inhibitors reduced weight more than metformin (range of between-group differences, Ϫ1.3 to Ϫ1.4 kg) (64, 66) or DPP-4 inhibitors (betweengroup difference, Ϫ2.5 to Ϫ2.7 kg) (88) and that DPP-4 inhibitors reduced weight more than thiazolidinediones (range of between-group differences, Ϫ2.3 to Ϫ2.5 kg) (37, 89) . High-quality evidence showed that sulfonylureas caused less weight gain than thiazolidinediones (pooled mean between-group difference, 1.2 kg [CI, 0.6 to 1.8 kg]) (35, 41, 43, 44, 50, 52, 90) . Moderatequality evidence indicated that DPP-4 inhibitors were favored over sulfonylureas (range of between-group differences, 0.7 to 1.8 kg) (61-63).
Monotherapy Versus Combination Therapy. Highquality evidence showed that metformin monotherapy reduced weight more than metformin plus a thiazolidinedione (pooled between-group difference, Ϫ2.2 kg [CI, Ϫ2.6 to Ϫ1.9 kg]) (26, 36, 63, (91) (92) (93) or metformin plus a sulfonylurea (pooled between-group difference, Ϫ2.2 kg [CI, Ϫ3.4 to Ϫ1.0 kg]) (94 -103) . High-quality evidence showed no difference in mean weight between metformin monotherapy and metformin plus a DPP-4 inhibitor (53, 56, 57, 59, 63, 67, 69, (103) (104) (105) (106) (107) (108) (109) (110) (111) (112) (113) (114) (115) . Metformin plus an SGLT-2 inhibitor was superior to metformin monotherapy for weight reduction (highquality evidence; pooled between-group difference, 2.0 kg [CI, 1.5 to 2.5 kg]) (64, 67, 69, 116, 117) .
Combination Therapy Versus Combination Therapy. The combination of metformin plus a DPP-4 inhibitor was superior for weight reduction compared with metformin plus a thiazolidinedione (moderatequality evidence; pooled mean between-group difference, 2.7 kg [CI, 0.8 to 4.5 kg]) (63, 76 -78) and compared with metformin plus a sulfonylurea (high-quality evidence; pooled mean between-group difference, 2.2 kg [CI, 1.8 to 2.5 kg]) (103, 118 -121) . High-quality evidence showed that the combination of metformin plus an SGLT-2 inhibitor was superior to metformin plus a sulfonylurea (pooled mean between-group difference, 4.7 kg [CI, 4.4 to 5.0 kg]) (72-74). (64, 65) . The evidence was insufficient to draw conclusions regarding the effects on heart rate of any monotherapy comparisons.
Monotherapy Versus Combination Therapy. Highquality evidence showed that metformin plus an SGLT-2 inhibitor reduced systolic blood pressure more than metformin alone (pooled between-group difference, 4.4 mm Hg [CI, 2.9 to 6.0 mm Hg]) (64, 67-69, 111, 116, 117, 122-124) .
The evidence was insufficient to draw conclusions regarding the effects on heart rate of any metformin combination therapy compared with metformin alone.
Combination Therapy Versus Combination Therapy. The combination of metformin and an SGLT-2 inhibitor reduced systolic blood pressure more than that of metformin and a sulfonylurea (high-quality evidence; pooled between-group difference, 5.1 mm Hg [CI, 4.2 to 6.0 mm Hg]) (74, 75, 114) or metformin and a DPP-4 inhibitor (moderate-quality evidence; pooled between-group difference, 4.1 mm Hg [CI, 3.6 to 4.6 mm Hg]) (67-70).
Moderate-quality evidence indicated that the combination of metformin and an SGLT-2 inhibitor increased heart rate less than metformin plus a sulfonylurea (pooled between-group difference, 1.5 beats/min [CI, 0.6 to 2.3 beats/min]) (72-74).
COMPARATIVE HARMS OF ORAL MEDICATIONS FOR TYPE 2 DIABETES Hypoglycemia
Moderate-quality evidence showed that metformin monotherapy was associated with a lower risk for mild, moderate, or total hypoglycemia than metformin plus a sulfonylurea (94, 95, 97, (101) (102) (103) (125) (126) (127) (128) . Moderatequality evidence also showed that monotherapy with either metformin (37) or a thiazolidinedione (9, 43) was associated with a lower risk for severe hypoglycemia than sulfonylureas. Moderate-quality evidence also showed that monotherapy with a DPP-4 inhibitor (61-63, 129) was associated with a lower risk for mild, moderate, or total hypoglycemia than sulfonylureas.
The combination of metformin and a DPP-4 inhibitor was associated with a lower risk for severe hypoglycemia than metformin plus a sulfonylurea (high-quality evidence) (118 -120, 130 -133) . Moderate-quality evidence showed that metformin plus an SGLT-2 inhibitor was associated with a lower risk for severe hypoglycemia than metformin plus a sulfonylurea (74, 75, 114) .
Gastrointestinal Side Effects
High-quality evidence showed no difference between thiazolidinediones and sulfonylureas for gastrointestinal side effects (9, 41, 43, 44, 134). Moderatequality evidence indicated no difference between metformin plus a thiazolidinedione and metformin plus a sulfonylurea (82) (83) (84) (85) 87) .
Genital Mycotic Infections
The SGLT-2 inhibitors, used alone or combined with metformin, increased the risk for genital mycotic infections compared with all other monotherapies or combination therapies. Metformin was associated with fewer genital mycotic infections than SGLT-2 inhibitors (moderate-quality evidence) (64, 65) .
High-quality evidence showed that metformin monotherapy was associated with a lower risk for genital mycotic infections than metformin plus an SGLT-2 inhibitor (64, 67, 68, 116, 117, 122, 135, 136) . The combination of metformin and a DPP-4 inhibitor was associated with a lower risk for genital mycotic infections than metformin plus an SGLT-2 inhibitor (moderatequality evidence) (66 -70) . High-quality evidence showed that metformin plus a sulfonylurea was associated with a lower risk for genital mycotic infections than metformin plus an SGLT-2 inhibitor (71, 74, 75, 114) .
MULTIPLE CHRONIC CONDITIONS
Patients with multiple chronic conditions often were excluded from the studies included in the systematic review.
SUMMARY
Although all oral diabetes medications reduced HbA 1c levels, the DPP-4 inhibitors were inferior to metformin and sulfonylureas for this outcome. Metformin had a greater benefit on weight than all agents except the SGLT-2 inhibitors, and SGLT-2 inhibitors were more effective than metformin in reducing blood pressure. Combination therapies with metformin and an SGLT-2 or a DPP-4 inhibitor were superior to metformin alone in reducing HbA 1c levels, weight, and blood pressure. Head-to-head comparisons of various combination therapies showed that metformin plus an SGLT-2 inhibitor was superior to metformin plus a DPP-4 inhibitor or metformin plus a sulfonylurea in reducing HbA 1c levels, although the CGC felt that these differences were of dubious clinical importance. Metformin monotherapy was associated with a low risk for hypoglycemia compared with other monotherapies. Evidence showed that sulfonylureas increased the risk for hypoglycemia, thiazolidinediones for congestive heart failure, and SGLT-2 inhibitors for genital mycotic infections. Thiazolidinediones and sulfonylureas were associated with weight gain when compared with metformin, DPP-4 inhibitors, and SGLT-2 inhibitors.
The CGC generally agreed with the evidence review that all evidence from comparisons of monotherapies and combination therapies with respect to overall and cardiovascular mortality, as well as cardiovascular morbidity, was of low quality. However, the committee felt that the evidence showing greater cardiovascular mortality with sulfonylureas than metformin mono- All combination therapies with metformin were superior to metformin monotherapy.
Weight
Metformin was better than thiazolidinediones, sulfonylureas, or DPP-4 inhibitors for weight.
Combinations of metformin and SGLT-2 inhibitor agonists reduced weight more than metformin monotherapy.
Thiazolidinediones and sulfonylureas, either alone or in combination therapy, were associated with worse weight outcomes.
Systolic Blood Pressure
SGLT-2 inhibitors, as monotherapy or combined with metformin, reduced systolic blood pressure compared with metformin monotherapy. Recommendation 2: ACP recommends that clinicians consider adding either a sulfonylurea, a thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considered. (Grade: weak recommendation; moderate-quality evidence.) ACP recommends that clinicians and patients select among medications after discussing benefits, adverse effects, and costs.
Clinical Considerations
Nonpharmacologic therapy includes dietary modifications, regular exercise, lifestyle modifications, and weight loss.
Management of type 2 diabetes often involves pharmacologic and nonpharmacologic therapies and includes patient education, evaluation, patient self-management for microvascular and macrovascular complications, treatment of hyperglycemia, and minimization of cardiovascular and other long-term risk factors.
Initiation of pharmacologic therapy is an important approach for the effective management of type 2 diabetes when weight loss or lifestyle modification fails.
Metformin monotherapy effectively decreases glycemic levels when used in monotherapy and combination therapy with a second agent. Metformin also reduces body weight.
Although combination therapy reduces HbA 1c levels more effectively than monotherapy, it is associated with more adverse events.
The DPP-4 inhibitors saxagliptin and alogliptin may increase the risk for heart failure, especially in patients who already have heart or kidney disease.
Metformin is considered safe for patients with mild chronic kidney disease and some patients with moderate kidney impairment (but is contraindicated in those with an estimated glomerular filtration rate <30 mL/min/1.73 m 2 ).
DPP-4 = dipeptidyl peptidase-4; HbA 1c = hemoglobin A 1c ; SGLT-2 = sodium-glucose cotransporter-2. 
RECOMMENDATIONS
Recommendation 1: ACP recommends that clinicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to improve glycemic control. (Grade: strong recommendation; moderate-quality evidence)
Metformin is effective in reducing glycemic levels, is associated with weight loss and fewer hypoglycemic episodes, and is cheaper than most other pharmacologic agents. Although the evidence was considered low quality, metformin may have an advantage over sulfonylurea monotherapy in terms of cardiovascular mortality. Therefore, unless contraindicated, metformin is the drug of choice for patients with type 2 diabetes, in addition to lifestyle modification.
As defined by the FDA, metformin is contraindicated in patients with decreased tissue perfusion or hemodynamic instability, advanced liver disease, alcohol abuse, acute unstable congestive heart failure, or any Combination therapies with metformin were more effective than metformin monotherapy in reducing HbA 1c levels, weight, and blood pressure in patients with type 2 diabetes. This recommendation is graded as weak because of the fine balance between benefits and harms for the various drug combinations. See Table 2 for a summary of the comparative benefits and harms of metformin combination therapies as well as the adverse effects and cost of each medication. The evidence review did not include therapies combining more than 2 agents. Combination therapies also were associated with an increased risk for adverse effects compared with monotherapy.
Sulfonylureas have been used for many years and are the least expensive oral agent to add to metformin. However, sulfonylureas, both alone and combined with other agents, are associated with an increased risk for mild, moderate, or severe hypoglycemia as well as weight gain. The evidence review did not address medication switching for patients currently taking sulfonylureas. Regarding patients whose glycemic levels are adequately controlled and who do not have adverse effects with sulfonylureas, keeping them on this drug may be reasonable.
The SGLT-2 inhibitors are favored over sulfonylureas as an add-on to metformin therapy in terms of cardiovascular mortality, HbA 1c , weight, systolic blood pressure, and heart rate and are favored over DPP-4 inhibitors as an add-on to metformin therapy in terms of weight and systolic blood pressure. As an add-on to metformin therapy, DPP-4 inhibitors are favored over sulfonylureas for long-term all-cause mortality, longterm cardiovascular mortality, and cardiovascular morbidity; over pioglitazone for short-term cardiovascular morbidity; and over sulfonylureas or thiazolidinediones for weight.
Each class of drugs is associated with adverse effects, which are summarized in Table 2 . The FDA warned that the DPP-4 inhibitors saxagliptin and alogliptin may increase the risk for heart failure, especially in patients who already have heart or kidney disease (138). The SGLT-2 inhibitors are associated with an increased risk for genital mycotic infections. Sulfonylureas are associated with an increased risk for hypoglycemia.
Although this guideline addresses only oral pharmacologic therapy, patients with persistent hyperglycemia despite oral agents and lifestyle interventions may need insulin therapy.
HIGH-VALUE CARE
Oral pharmacologic therapy with metformin (unless contraindicated) is an effective management strategy. It is cheaper and more effective than most other pharmacologic agents and is associated with fewer adverse effects; of note, it does not result in weight gain. Adding a second agent to metformin may provide additional benefits; however, the increased cost may not always support the added benefit, particularly for the more expensive, newer medications.
INSUFFICIENT AREAS OF EVIDENCE
Insufficient evidence exists for clinical outcomes, including mortality, cardiovascular morbidity, and microor macrovascular outcomes, for most drugs and drug comparisons. The evidence review did not address whether patients who are already taking sulfonylureas and have stable HbA 1c levels should switch to another medication. No data exist regarding the best time to add oral therapies to lifestyle modifications.
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Key Question 2 a. In adults aged 18 years or older with type 2 diabetes mellitus, what is the comparative effectiveness of the specified monotherapy FDA-approved diabetes medications for the long-term clinical outcomes of allcause mortality, cardiovascular and cerebrovascular morbidity and mortality, retinopathy, nephropathy, and neuropathy?
b. In adults aged 18 years or older with type 2 diabetes mellitus, what is the comparative effectiveness of the specified metformin-based combinations of FDA-approved diabetes medications for the long-term clinical outcomes of all-cause mortality, cardiovascular and cerebrovascular morbidity and mortality, retinopathy, nephropathy, and neuropathy? Key Question 3 a. In adults aged 18 years or older with type 2 diabetes mellitus, what is the comparative safety of the specified monotherapy FDA-approved diabetes medications regarding liver injury, lactic acidosis, pancreatitis, hypoglycemia, congestive heart failure, cancer, severe allergic reactions, macular edema or decreased vision, and gastrointestinal side effects; for comparisons including SGLT-2 inhibitors, what is the comparative safety regarding urinary tract infections, impaired renal function, genital mycotic infections, fracture, and volume depletion?
b. In adults aged 18 years or older with type 2 diabetes mellitus, what is the comparative safety of the specified metformin-based combinations of FDAapproved diabetes medications regarding liver injury, lactic acidosis, pancreatitis, hypoglycemia, congestive heart failure, cancer, severe allergic reactions, macular edema or decreased vision, and gastrointestinal side effects; for comparisons including SGLT-2 inhibitors, what is the comparative safety regarding urinary tract infections, impaired renal function, genital mycotic infections, fracture, and volume depletion?
Key Question 4
Do the comparative safety and effectiveness of these treatments differ across subgroups defined by the age, sex, race/ethnicity, and body mass index of adults with type 2 diabetes?
Search Strategy
To update the 2011 systematic review (18), the reviewers searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for Englishlanguage studies published from April 2009 through March 2015 and updated through December 2015. Studies were limited to randomized, controlled trials for key question 1; high-quality observational studies also were considered for key questions 2 and 3.
Meta-analysis
The reviewers conducted a meta-analysis when data were sufficient and studies were sufficiently homogeneous with respect to study population characteristics, study duration, and medication dosing.
Quality Assessment
The reviewers used the Jadad criteria (139) to assess risk of bias in randomized, controlled trials and the Downs and Black tool (140) to assess nonrandomized trials and observational studies.
Population Studied
The study population included adults with type 2 diabetes, non-insulin-dependent diabetes mellitus, or adult-onset diabetes.
Interventions Evaluated
Evaluated pharmacologic interventions included metformin, thiazolidinediones, sulfonylureas, DPP-4 inhibitors, and SGLT-2 inhibitors. Although the GLP-1 receptor agonists were not evaluated in the guideline, they were included in the full evidence review (5).
Comparators
Monotherapies were compared with one another, metformin was compared with combination therapies including metformin, and metformin-based combination therapies were compared with one another.
Outcomes
Outcomes evaluated included all-cause mortality, cardiovascular and cerebrovascular morbidity and mortality, retinopathy, nephropathy, neuropathy, HbA 1c , weight, systolic blood pressure, heart rate, and harms.
Timing
In the studies evaluated, oral pharmacologic interventions were used for more than 3 months.
Setting
The setting was outpatient as well as inpatient.
Target Audience
The target audience for this guideline includes all clinicians.
Target Patient Population
The target patient population includes all adults with type 2 diabetes.
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